Zacks Investment Research downgraded shares of NAVIDEA BIOPHAR (NAVB) from N/A to NEUTRAL on March 11, 2014, with a target price of $2.30.
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NAVIDEA BIOPHAR (NAVB),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment